Drug Landscape ›
perindopril, indapamide , amlodipine ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Fatigue — 2 reports (16.67%) Vomiting — 2 reports (16.67%) Abdominal Pain Upper — 1 report (8.33%) Acidosis — 1 report (8.33%) Acute Kidney Injury — 1 report (8.33%) Acute Myocardial Infarction — 1 report (8.33%) Adverse Drug Reaction — 1 report (8.33%) Blood Creatinine Increased — 1 report (8.33%) Blood Glucose Increased — 1 report (8.33%) Bradyarrhythmia — 1 report (8.33%)
Source database →
perindopril, indapamide , amlodipine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is perindopril, indapamide , amlodipine approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for perindopril, indapamide , amlodipine in United States?
University of Roma La Sapienza is the originator. The local marketing authorisation holder may differ — check the official source linked above.